Could less be more? new study tests lower doses of cancer drug

NCT ID NCT06066138

Recruiting now Disease control Sponsor: National Cancer Institute (NCI) Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Aug 04, 2026 · Updated 9 times

Summary

This study is testing whether giving lower, less frequent doses of the cancer drug atezolizumab can still keep enough drug in the blood to fight cancer. About 30 adults with certain advanced cancers (like lung cancer or melanoma) will start with standard doses, then switch to a lower dose based on their blood levels. The goal is to see if this approach is feasible and could reduce side effects.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: atezolizumab (a cancer immunotherapy drug)
What this could lead to: If successful, this could show that lower doses of atezolizumab work just as well, potentially reducing side effects and treatment burden for patients.
What could go wrong: This is a very early phase 1 study with only 30 participants, so results may not apply broadly. Lower doses might not control cancer as effectively.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for LOCALLY ADVANCED ALVEOLAR SOFT PART SARCOMA are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

alveolar soft part sarcoma cutaneous melanoma hepatocellular carcinoma melanoma metastatic melanoma non-small cell lung carcinoma small cell lung carcinoma

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

LOCALLY ADVANCED ALVEOLAR SOFT PART SARCOMA LOCALLY ADVANCED HEPATOCELLULAR CARCINOMA LOCALLY ADVANCED MELANOMA LOCALLY ADVANCED NON-SMALL CELL LUNG CANCER LOCALLY ADVANCED SMALL CELL LUNG CANCER METASTATIC ALVEOLAR SOFT PART SARCOMA METASTATIC HEPATOCELLULAR CARCINOMA METASTATIC MELANOMA METASTATIC NON-SMALL CELL LUNG CANCER METASTATIC SMALL CELL LUNG CANCER

Contacts and locations

Locations

National Institutes of Health Clinical Center
RECRUITING

Bethesda, Maryland, 20892, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.